Ulla Wilking
Karolinska Institutet(SE)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Economic and Financial Impacts of Cancer, Health Systems, Economic Evaluations, Quality of Life, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression(2012)532 cited
- → HER2 status in a population-derived breast cancer cohort: discordances during tumor progression(2010)118 cited
- → Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting(2016)45 cited
- → Discordance in hormone receptor status in breast cancer during tumor progression.(2010)41 cited
- → The value of anticancer drugs — a regulatory view(2021)32 cited
- → Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden(2010)13 cited
- → HER2 gene amplification (HER2) and hormone receptor expression (ER/PR) in early (EBC) and metastatic breast cancer (MBC) in the same patients(2007)9 cited
- → Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study(2023)7 cited
- → Abstract S3-5: Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression(2010)6 cited
- → Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity(2020)6 cited